Opium (Opioid) Addiction - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Opium (Opioid) Addiction - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Opium (Opioid) Addiction - Pipeline Review, H1 2015', provides an overview of the Opium (Opioid) Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Opium (Opioid) Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Opium (Opioid) Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Opium (Opioid) Addiction Overview 9
Therapeutics Development 10
Pipeline Products for Opium (Opioid) Addiction - Overview 10
Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis 11
Opium (Opioid) Addiction - Therapeutics under Development by Companies 12
Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes 13
Opium (Opioid) Addiction - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Opium (Opioid) Addiction - Products under Development by Companies 17
Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes 19
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 20
Acura Pharmaceuticals, Inc. 20
Alkermes Plc 21
BioDelivery Sciences International, Inc. 22
Camurus AB 23
Celtic Pharmaceutical Holdings L.P. 24
D&A Pharma SAS 25
Foresee Pharmaceuticals, LLC 26
Heron Therapeutics, Inc. 27
Indivior PLC 28
INSYS Therapeutics, Inc. 29
Omeros Corporation 30
Pfizer Inc. 31
Relmada Therapeutics, Inc. 32
Titan Pharmaceuticals, Inc. 33
Zynerba Pharmaceuticals, Inc. 34
Opium (Opioid) Addiction - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Buprenorphine Hemiadipate Hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
buprenorphine hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
buprenorphine hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
buprenorphine hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
buprenorphine hydrochloride depot - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
buprenorphine hydrochloride ER - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
buprenorphine hydrochloride long acting - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
buprenorphine hydrochloride SR - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
cannabidiol - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
cannabidiol - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
FP-004 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MAL - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
methadone IR - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
naltrexone - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
naltrexone - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
OMS-405 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
OMS-527 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
PF-5006739 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
samidorphan - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
TA-CD - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Vaccine for Opium Addiction - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Opium (Opioid) Addiction - Recent Pipeline Updates 73
Opium (Opioid) Addiction - Dormant Projects 77
Opium (Opioid) Addiction - Discontinued Products 78
Opium (Opioid) Addiction - Product Development Milestones 79
Featured News & Press Releases 79
Apr 02, 2015: Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market 79
Mar 24, 2015: Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine 80
Feb 24, 2015: Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine 80
Jan 06, 2015: Titan Pharmaceuticals to Present at 8th Annual OneMedForum 80
Dec 01, 2014: Titan Pharmaceuticals to Present at LD Micro Conference 81
Nov 20, 2014: Titan Pharmaceuticals Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence 81
Sep 23, 2014: Titan Pharmaceuticals Announces Enrollment Reaches Halfway Mark in Phase 3 Study of Probuphine for Opioid Dependence 82
Jul 21, 2014: Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence 83
Apr 30, 2014: Braeburn Pharmaceuticals To Initiate New Clinical Study For Probuphine Following Clear Guidance From FDA 83
Dec 23, 2013: Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application 84
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H1 2015 10
Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Opium (Opioid) Addiction - Pipeline by Acura Pharmaceuticals, Inc., H1 2015 20
Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H1 2015 21
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H1 2015 22
Opium (Opioid) Addiction - Pipeline by Camurus AB, H1 2015 23
Opium (Opioid) Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2015 24
Opium (Opioid) Addiction - Pipeline by D&A Pharma SAS, H1 2015 25
Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 26
Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H1 2015 27
Opium (Opioid) Addiction - Pipeline by Indivior PLC, H1 2015 28
Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H1 2015 29
Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H1 2015 30
Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H1 2015 31
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H1 2015 32
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H1 2015 33
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 34
Assessment by Monotherapy Products, H1 2015 35
Assessment by Combination Products, H1 2015 36
Number of Products by Stage and Target, H1 2015 38
Number of Products by Stage and Mechanism of Action, H1 2015 40
Number of Products by Stage and Route of Administration, H1 2015 42
Number of Products by Stage and Molecule Type, H1 2015 44
Opium (Opioid) Addiction Therapeutics - Recent Pipeline Updates, H1 2015 73
Opium (Opioid) Addiction - Dormant Projects, H1 2015 77
Opium (Opioid) Addiction - Discontinued Products, H1 2015 78